Determinants of time to access to EMA-approved cancer drugs in Spanish NHS in the past decade: a two cohorts study.

BACKGROUND: Spain is the fourth largest pharmaceutical market in Europe, yet the time to reimbursement for cancer drugs has been considerably longer than in other European countries in recent years. OBJECTIVE: This study aimed to analyse the key fact…

Preview only. Read the full abstract at the source